Relationship Between Anogenital Distance, Serum AMH, and mTESE in Klinefelter Syndrome (KS)

Cairo University (CU)

Status: Completed

Conditions: Azoospermia Anogenital Distance AMH

Treatments: Other: mTESE (microscopic testicular sperm extraction)

Study type: Observational

Funder types: Other

Identifiers

NCT06396117

AND AMH

Details and patient eligibility

About

Azoospermia, the absence of sperm in the ejaculate, affects approximately 1% of males and 15% of infertile men. Non-obstructive azoospermia (NOA) accounts for 60% of azoospermic patients, who rely solely on testicular sperm extraction (TESE) surgery for sperm harvesting. While conventional TESE (cTESE) and microdissection TESE (mTESE) are preferred methods, the lack of predictive biomarkers for successful sperm retrieval (SR) renders treatment unnecessary for many NOA males. However, research suggests that anti-Mullerian hormone (AMH) and anogenital distance (AGD) may serve as predictors of positive SR at mTESE in NOA males. AGD, a marker of fetal androgen disruption and adult outcomes, may also assess male reproductive potential by predicting normal genital growth and sperm creation. A cross-sectional study found a positive correlation between AGD and total sperm count, concentration, and motility in infertile men aged 25-38, providing valuable prognostic insights for azoospermic men.

Full description

Azoospermia, which is defined as the lack of spermatozoa in the ejaculate, is a condition that affects around one percent of males and fifteen percent of men who are infertile. Sixty percent of azoospermic patients are affected by non-obstructive azoospermia, often known as NOA.

To harvest sperm for assisted reproductive technology (ART), this subset of men has no other choice except to undergo testicular sperm extraction (TESE) surgery.

Conventional TESE (cTESE) and microdissection TESE (mTESE) are the most preferred procedures in terms of sperm retrieval (SR) rates and the decrease of damage caused by excision. Studies have revealed varying percentages of positive SR, ranging from thirty percent to sixty percent.

This treatment is not necessary for a significant number of NOA boys because there are no biomarkers or procedures that are clinically acceptable that can predict a positive SR score at mTESE.

According to earlier research, anti-mullerian hormone (AMH), which is a homodimeric glycoprotein belonging to the family of transforming growth factor-b, has the potential to predict either a positive or negative significant difference (SR) at mTESE in iNOA. Throughout the course of development, Sertoli cells (SCs) secrete Amyloid-beta (AMH) in order to regress the Mullerian ducts and ensure that male sex differentiation occurs. AMH levels drop significantly when the development of puberty in males and the maturation of SCs occurs. It has been suggested that this hormone, which is solely produced by spermatocytes in males, can be used as an indirect marker of spermatogenesis, maturation of spermatocytes, and immaturity of the prepubertal testes.

A noninvasive method known as anogenital distance has recently been applied for the purpose of predicting and diagnosing disorders. There are two different measurements of the anogenital distance (AGD) for both men and women. AGD is a marker that indicates fetal androgen dysregulation as well as negative effects in adulthood. AGD is a unique method that can be used to evaluate the reproductive potential of males because it has the capacity to predict normal male genital growth and the production of sperm. It may also assist medical professionals in providing prognostic information to men who are azoospermic.

AGD AS was found to have a positive correlation with total sperm count, concentration, and motility in a cross-sectional study where the participants were infertile men between the ages of 25 and 38.

Enrollment: 56 patients

Sex: Male

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All NOA patients underwent mTESE at the Andrology department, Kasr Al-Ainy hospitals

Exclusion criteria

• patients with

  1. Obstructive azoospermia
  2. Retrograde Ejaculation
  3. Men with hypogonadotropic hypogonadism

Trial design

56 participants in 2 patient groups

patients who have KS

Description:

Group one is patients with Klinefelter syndrome confirmed as 47, XXY on karyotyping undergoing mTESE for non-obstructive azoospermia

Treatment:

Other: mTESE (microscopic testicular sperm extraction)

Patient who does not have KS

Description:

Group two consists of patients with a normal karyotyping undergoing mTESE for non-obstructive azoospermia

Treatment:

Other: mTESE (microscopic testicular sperm extraction)